ACH-3102: Phase Ib data

A Phase Ib trial in 14 patients with HCV genotype 1a infection showed that a single dose of 300 mg ACH-3102 led to a mean maximum HCV RNA reduction from baseline of 3.93 log10 IU/mL vs. 0.78 log10 IU/mL for placebo. The mean maximum HCV RNA reduction for a single 50 mg dose of ACH-3102 was 3.78 log10 IU/mL and 3.52 log10 IU/mL for a single 150 mg dose of ACH-3102. Furthermore, mean viral load was 2.76 log10 IU/mL below baseline at day 8 following a single dose of 300 mg ACH-3102. ACH-3102 was well tolerated with no serious adverse events reported and no patient discontinuations. ...